Whether Hippo pathway dysregulation correlates with VHL, SETD2, or BAP2 mutations during RCC, and/or YAP/TAZ activation in such settings increases the risk of disease development, requires additional studies. This evidence concerns the gene VHL and renal cell carcinoma.